FDA inspection
Raritan Pharmaceuticals, Inc.: FDA inspection ending Oct 20, 2016
FDA inspection 995165 · Official Action Indicated (OAI) · East Brunswick, NJ
Key facts
| Inspection ID | 995165 |
|---|---|
| Firm | Raritan Pharmaceuticals, Inc. |
| FEI number | 3004083931 |
| Address | 8 Joanna Ct |
| City | East Brunswick |
| State | NJ |
| ZIP | 08816 |
| Country | United States |
| Fiscal year | 2017 |
| Inspection end date | Oct 20, 2016 |
| Classification | Official Action Indicated (OAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
| Warning letter | 516099 |
At a glance
- 10–99 Citations
- 1–9 Posted citations
- Yes Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data